Patents by Inventor Guanglin Luo

Guanglin Luo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIARYL KINASE INHIBITORS
    Publication number: 20190367508
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: June 18, 2019
    Publication date: December 5, 2019
    Inventors: Guanglin Luo, Carolyn Diane Dzierba, John E. Macor
  • GSK-3 INHIBITORS
    Publication number: 20190315714
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
    Type: Application
    Filed: November 27, 2017
    Publication date: October 17, 2019
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Guanglin Luo, Ling Chen, Prasanna Sivaprakasam, Gene M. Dubowchik, Swannee E. Jacutin-Porte, John E. Macor
  • Biaryl kinase inhibitors
    Patent number: 10351563
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: July 16, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventor: Guanglin Luo
  • ACYL SULFONAMIDE NaV1.7 INHIBITORS
    Publication number: 20190119209
    Abstract: The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Application
    Filed: April 19, 2017
    Publication date: April 25, 2019
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Guanglin Luo, Ling Chen
  • Biaryl kinase inhibitors
    Patent number: 10246469
    Abstract: The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: April 2, 2019
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: Joanne J. Bronson, Ling Chen, Jonathan L. Ditta, Carolyn Diane Dzierba, Prasada Rao Jalagam, Guanglin Luo, John E. Macor, Tarun Kumar Maishal, Susheel Jethanand Nara, Ramkumar Rajamani, Ramesh Kumar Sistla, Soodamani Thangavel
  • BIARYL KINASE INHIBITORS
    Publication number: 20190048006
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: October 23, 2018
    Publication date: February 14, 2019
    Inventor: GUANGLIN LUO
  • BIARYL KINASE INHIBITORS
    Publication number: 20190040080
    Abstract: The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.
    Type: Application
    Filed: September 29, 2016
    Publication date: February 7, 2019
    Inventors: Joanne J. BRONSON, Ling CHEN, Jonathan L. DITTA, Carolyn Diane DZIERBA, Prasada Rao JALAGAM, Guanglin LUO, John E. MACOR, Tarun Kumar MAISHAL, Susheel Jethanand Nara, Ramkumar RAJAMANI, Ramesh Kumar SISTLA, Soodamani THANGAVEL
  • Biaryl kinase inhibitors
    Patent number: 10155760
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: December 18, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Carolyn Diane Dzierba, John E. Macor
  • BIARYL KINASE INHIBITORS
    Publication number: 20180346440
    Abstract: The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.
    Type: Application
    Filed: September 29, 2016
    Publication date: December 6, 2018
    Inventors: Joanne J. Bronson, Ling Chen, Jonathan L. Ditta, Carolyn Diane Dzierba, Prasada Rao Jalagam, Guanglin Luo, John E. Macor, Tarun Kumar Maishal, Susheel Jethanand Nara, Ramkumar Rajamani, Ramesh Kumar Sistla, Soodamani Thangavel
  • BIARYL KINASE INHIBITORS
    Publication number: 20180134704
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: January 9, 2018
    Publication date: May 17, 2018
    Inventors: Guanglin Luo, Ling Chen, Carolyn Diane Dzierba, Jonathan L. Ditta, John E. Macor, Joanne J. Bronson
  • Biaryl kinase inhibitors
    Patent number: 9902722
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: February 27, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Ling Chen, Carolyn Diane Dzierba, Jonathan L. Ditta, John E. Macor, Joanne J. Bronson
  • Substituted pyridine derivatives useful as GSK-3 inhibitors
    Patent number: 9809573
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: November 7, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Ling Chen, Gene M. Dubowchik, Swanee E. Jacutin-Porte, Prasanna Sivaprakasam, John E. Macor
  • GSK-3 inhibitors
    Patent number: 9718804
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: August 1, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Ling Chen, Gene M. Dubowchik, Swanee E. Jacutin-Porte, Vivekananda M. Vrudhula, Senliang Pan, Prasanna Sivaprakasam, John E. Macor
  • BIARYL KINASE INHIBITORS
    Publication number: 20170183340
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Application
    Filed: April 1, 2015
    Publication date: June 29, 2017
    Inventors: Guanglin Luo, Ling Chen, Carolyn Diane Dzierba, Jonathan L. Ditta, John E. Macor, Joanne J. Bronson
  • Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors
    Publication number: 20160289210
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: November 3, 2014
    Publication date: October 6, 2016
    Inventors: Guanglin Luo, Ling Chen, Gene M. Dubowchik, Swanee E. Jacutin-Porte, Prasanna Sivaprakasam, John E. Macor
  • GSK-3 INHIBITORS
    Publication number: 20160272621
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.
    Type: Application
    Filed: November 3, 2014
    Publication date: September 22, 2016
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Guanglin Luo, Ling Chen, Gene M. Dubowchik, Swanee E. Jacutin-Porte, Vivekananda M. Vrudhula, Senliang Pan, Prasanna Sivaprakasam, John E. Macor
  • CGRP receptor antagonists
    Patent number: 8748429
    Abstract: The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: June 10, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Gene M. Dubowchik, John E. Macor, Ling Chen
  • CGRP Receptor Antagonists
    Publication number: 20130096130
    Abstract: The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: April 4, 2012
    Publication date: April 18, 2013
    Inventors: Guanglin Luo, Gene M. Dubowchik, John E. Macor, Ling Chen
  • CGRP receptor antagonists
    Patent number: 8314117
    Abstract: The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: November 20, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Gene M. Dubowchik, John E. Macor
  • CGRP receptor antagonists
    Patent number: 8143403
    Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: March 27, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: David K. Leahy, Yu Fan, Lopa V. Desai, Ronald L. Hanson, Thorsten Rosner, Guanglin Luo